Inhibition of EGFR kinase activity and autophosphorylation by Iressa.

Slides:

Advertisements

Similar presentations

Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients

Advertisements

KG-501 suppresses NSCLC/IL-1β CM–induced migration of HUVECs by regulating IL-1β–induced CXC chemokine gene expression in NSCLC cells. KG-501 suppresses.

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model by Eline Menu, Helena Jernberg-Wiklund,

Antiproliferative effects of erlotinib correlate poorly with abundance of p-EGFR. Antiproliferative effects of erlotinib correlate poorly with abundance.

Small-molecule inhibitor QLT-0267 suppresses ILK activity and inhibits its downstream signaling. Small-molecule inhibitor QLT-0267 suppresses ILK activity.

Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6 by Hideaki Ishikawa, Naohiro Tsuyama, Saeid.

Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung.

Angiotensin II-induced growth of vascular smooth muscle cells requires an Src- dependent activation of the epidermal growth factor receptor1 Dirk Bokemeyer,

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Ganglioside GM3 Promotes Carcinoma Cell Proliferation via Urokinase Plasminogen Activator-Induced Extracellular Signal-Regulated Kinase-Independent p70S6.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

Volume 23, Issue 6, Pages (June 2013)

Lysophosphatidic acid-induced proliferation in opossum kidney proximal tubular cells: Role of PI 3-kinase and ERK Richard J. Dixon, Nigel J. Brunskill

PI(3,4,5)P3 releases SIN1-PH–mediated inhibition on mTOR-KD, leading to mTORC2 activation. PI(3,4,5)P3 releases SIN1-PH–mediated inhibition on mTOR-KD,

Volume 116, Issue 6, Pages (June 1999)

Nitric oxide decreases IGF-1 receptor function in vitro; glutathione depletion enhances this effect in vivo R.K. Studer, Ph.D. Osteoarthritis and Cartilage

Volume 96, Issue 5, Pages (March 1999)

p38 MAPK activation is required for phosphorylation of Akt at Ser473.

Regulation of protein kinase C ζ by PI 3-kinase and PDK-1

Tyrosine phosphorylations of both DAB1 and ABL are essential for invasion of colorectal cancer cells. Tyrosine phosphorylations of both DAB1 and ABL are.

TRAF4 is required for EGFR activation in response to EGF stimulation.

Distribution of phosphosites and PDGFRα activity in primary cultures.

Lapatinib reduces IGF-I signaling in trastuzumab-resistant cells.

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

Allopurinol up-regulates DR5 expression in PC-3 and DU145 cells.

Raghvendra Singh, Stelios T Andreadis Molecular Therapy

BCX inhibits lamellipodia formation in lung cells.

The sesquiterpene lactone PN up-regulates MDM2 and p53 proteins.

Biochemical characterization and localization of EGFRΔ768.

GA blocks HIF activity and reduces HIF target expression.

Cytotoxic activity of HER2-lytic hybrid peptide.

GR cells are dependent upon sustained CDC25C signaling as pharmacologic or genetic inhibition of CDC25C induce synthetic lethality. GR cells are dependent.

Gramicidin A (GA) decreases HIF protein expression in RCC cells.

Identification of NSC as a FADD-kinase inhibitor.

Effect of LY on phosphorylation of various MAP kinase substrates in HeLa cells in vitro. Effect of LY on phosphorylation of various MAP kinase.

Imatinib mesylate inhibits PDGF-mediated ERK and Akt activation.

CCG regulates cellular localization and blocks target gene expression of MRTF. A, SK-Mel-147 cells were cotransfected with RhoC and the SRE.L reporter.

Inhibition of stress-associated MAPK signaling attenuates SASP expression in CAFs. A, N-CAFs were treated with 100 nmol/L GEM plus DMSO or the above-listed.

The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle distribution. The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle.

Effect of G9a on the expression of GSH synthesis enzymes.

Bcl-2 and caspase inhibition fails to inhibit BAMLET-induced cytotoxicity in MCF-7 cells. Bcl-2 and caspase inhibition fails to inhibit BAMLET-induced.

LY induces cytotoxicity in hMECs via inhibition of Akt/p70S6K kinase activities. LY induces cytotoxicity in hMECs via inhibition of Akt/p70S6K.

Discovery of Gö6976-related potent reversible EGFR T790M inhibitors.

MDA-468TR-PTEN (with and without 100 ng/ml doxycycline) and MDA-468TR-vector (with dox) were serum starved overnight and the following day treated for.

Modeling of EGFR exon 20 insertions using the 3-dimensional structure of the EGFR kinase domain predicts different interactions with the erlotinib-binding.

The AKT–mTOR pathway controls PD-L1 protein expression.

Antitumor effects of celastrol in vitro and in vivo.

FACS analyses of the inhibitory effect induced by mixed docetaxel, gefitinib, and cyclopamine on EGF plus SHHNp–stimulated PC3 cells. FACS analyses of.

ERK reactivation following EGFR TKI treatment.

GS87 is a highly specific and potent GSK3 inhibitor that induces AML cell differentiation. GS87 is a highly specific and potent GSK3 inhibitor that induces.

Effect of coapplication of dexrazoxane and doxorubicin on DSB formation, TOP2A protein level, and apoptosis. Effect of coapplication of dexrazoxane and.

Drug interaction signatures for GIST and benign osteoma cell lines representing all combinatorial data compiled in a 9 × 9 drug matrix. Drug interaction.

PKCζ is tyrosine phosphorylated by EGF and contributes to EGF-induced activation of ERK in Mef cells. PKCζ is tyrosine phosphorylated by EGF and contributes.

Potential model of HMQ1611 inhibiting breast cancer cell proliferation

ABT-100 inhibits PI3K activity and p85 tyrosine phosphorylation.

IGF-II antibodies inhibited IGF-II-induced phosphorylation of IGF-IR and insulin receptor (IR) in the breast cancer MCF-7 cells. IGF-II antibodies inhibited.

WP1066 inhibits the progression of OCIM2 cells through the cell cycle.

by Dana S. Levy, Jason A. Kahana, and Rakesh Kumar

The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. Serum-starved.

AKT activation in HCC2429 is SRC- but not Notch-dependent.

Effect of bevacizumab on the proliferation of A2780 cells.

In silico, in vitro, and pharmacokinetic evaluation of the synthesized SANs. A, docking for sunitinib and SAN1–5 with estimated inhibition constants (Ki.

Double knockdown of HER2/EGFR abolishes HPSE nucleolar localization in 231BR3 cells. Double knockdown of HER2/EGFR abolishes HPSE nucleolar localization.

Expression and induction of HER2 and HPSE in 231BMBC cells.

Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105. Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105.

EGF induces HPSE nucleolar localization in human BMBC cells.

A, Pharmacologically inhibiting protein tyrosine kinases significantly reduces the viability of ATRT cell lines as compared with control HEK 293 cells.

Mechanism of ERM protein–dependent CD44 cleavage.

I3C reduces the level of Cdc25A protein in breast cancer cells.

DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.

Presentation transcript:

Inhibition of EGFR kinase activity and autophosphorylation by Iressa. Inhibition of EGFR kinase activity and autophosphorylation by Iressa. Inhibition of EGFR autophosphorylation on Tyr1173 by Iressa in Hec50co cells (A) and Ishikawa H cells (B). Cells were serum starved for 24 h and treated as indicated with 30 ng/mL EGF for 15 min with increasing concentrations of Iressa. Lane 1, untreated control; lane 2, cells treated with EGF; lane 3, cells treated with 1 μL DMSO (vehicle) and EGF; lane 4, cells treated with 40 μL DMSO (vehicle) and EGF; lane 5, cells treated with 0.1 μmol/L Iressa and EGF; lane 6, cells treated with 1 μmol/L Iressa and EGF; lane 7, cells treated with 5 μmol/L Iressa and EGF; lane 8, cells treated with 10 μmol/L Iressa and EGF; lane 9, cells treated with 20 μmol/L Iressa and EGF; lane 10, cells treated with 40 μmol/L Iressa and EGF. Iressa at all concentrations blocked EGFR autophosphorylation on Tyr1173. DMSO (1 μL) serves as a vehicle control for the cells treated with 0.1 μmol/L Iressa (lane 5), whereas lane 4 included a vehicle control of DMSO volume of 40 μL to compare to lane 10, where 40 μL Iressa in DMSO was used (total concentration of Iressa, 40 μmol/L). Enhanced phosphorylation of EGFR was observed in lane 4 (B) in the presence of a larger volume of DMSO vehicle for Hec50co cells. Nevertheless, this was completely blocked in the presence of Iressa as shown in lane 10. C, in vitro kinase assay of EGFR in Hec50co cells. Cells were treated as indicated with EGF, Iressa, or both after serum starvation for 24 h. Iressa (1 μmol/L) for 2 h blocked EGFR kinase activity and autophosphorylation on tyrosine residue Tyr1173. D, total EGFR in Ishikawa H and Hec50co cells. A comparable amount of EGFR total protein is present in the two cell lines. Lina Albitar et al. Mol Cancer Ther 2005;4:1891-1899 ©2005 by American Association for Cancer Research